{
  "docId": "019dd923-622c-750b-8b9b-a530d644219b",
  "docSlug": "2c06f582b147",
  "documentTitle": "Valeant Pharmaceuticals International (VRX)",
  "authorId": "01_Pershing_Square",
  "authorName": "Pershing Square Holdings",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2016-03-21 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 1,
  "pageCount": 1,
  "prevPage": null,
  "nextPage": null,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": "https://imgproxy.kitesheet.com/WKCYETnuiryVphSJAlUsJ1S8P9mh_FyMsCktxncmrbg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5qcGc",
  "slideHref": "/slides/019dd923-622c-750b-8b9b-a530d644219b/1",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-a530d644219b",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-a530d644219b.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a530d644219b#slide-1",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.43
      },
      "kind": "paragraph",
      "text": "About Pershing Square Holdings, Ltd. Pershing Square Holdings, Ltd. (PSH:NA) is an investment holding company structured as a closed end fund that makes concentrated investments principally in North American companies.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e34f870-bf6e-499b-b665-9b5f3fff4cf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Dear Pershing Square Investor, Today Valeant Pharmaceuticals International, Inc. issued a press release announcing developments at the company. Please find below a link to the press release on the Valeant web site.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aa39d54-cd21-48e3-91f8-1df81150c65e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "http://ir.valeant.com/news-releases/2016/03-21-2016-125936508",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cd0baa8-7fe3-4e02-bb3a-2d6389d00d8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.2,
        "x": 0.11,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "Kind regards, Pershing Square IR ir@persq.com",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb85cb89-1a68-47e1-a426-e0d9359ddab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "Amsterdam, 21 Mar. 2016 //- Pershing Square Holdings, Ltd. today released an email to investors. The text of the email is set forth below:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec4a212c-28df-4bee-b6e9-a94c18ba9c61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.54,
        "x": 0.23,
        "y": 0.09
      },
      "kind": "title",
      "text": "Pershing Square Holdings, Ltd. Communicates with Shareholders Regarding Developments at Valeant Pharmaceuticals International, Inc.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a44bcc93-f12b-4dc7-bbf0-b9438ac9c71e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 1,
      "from": 1,
      "beatId": "dbbad077-33ab-463d-bc8c-407beb569982",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Attention",
      "beatSlug": "aida-attention",
      "evidence": "Initial communication",
      "position": 0,
      "confidence": 0.6,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [],
  "imagePathAlt": "https://imgproxy.kitesheet.com/Oyvti9HrbGxoHIDQmTpy5KOXNk7aZbVQwcJzKG-OJ6w/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5wbmc",
  "thumbSrc": "https://imgproxy.kitesheet.com/SrNzrV_DxX1RetZwCUM2WjGoji6X1jBYpVdV_uwC4i8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5qcGc",
  "thumbSrcAlt": "https://imgproxy.kitesheet.com/sVNK-pNfB4oLnIXB6KA3gNqkN6euj7XkLj81I2e-Cdg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5wbmc"
}